VERTEX REPORTS PROGRESS ON CANCER STUDY

A A

Vertex Pharmaceuticals has announced clinical and research progress in its worldwide collaboration with Merck to develop aurora kinase inhibitors for the treatment of cancer.

In a Phase I clinical study in patients with solid tumor cancers, dosing with VX-680 (MK-0457) demonstrated activity on a clinically relevant biomarker, triggering achievement of a milestone under the contract. VX-680 is a small molecule inhibitor of aurora kinases and the lead development compound in the collaboration. In addition, Merck has selected a follow-on compound for development from a joint aurora kinase research program that is part of the collaboration.